Kodiak Sciences Upcoming Data Could Support Upside, UBS Says

MT newswire2026/09/24 16:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

12:45 PM EDT, 09/24/2026 (MT Newswires) -- Kodiak Sciences (KOD) upcoming phase III wet AMD data could provide upside following the stock's recent pullback, amid expectations that tarcocimab and KSI-501 will achieve non-inferiority, UBS said in a note. UBS expects tarcocimab to meet non-inferiority to Eylea 2mg in the DAYBREAK trial, with dosing intervals potentially reaching 3 to 3.5 months. The company is expected to report topline data by the end of September, with a presentation at the American Academy of Ophthalmology (AAO) on Oct. 9, UBS said. UBS also expects KSI-501 to meet non-inferiority, while any numerically superior trends would provide additional upside. The bank also expects December data as another potential catalyst. UBS maintained a buy rating with an $80 price target. Price: 30.78, Change: -0.74, Percent Change: -2.35

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

JPMorgan Private Bank believes that before interest rates reach their peak, it will be difficult to confirm a bottom for gold prices. Thin liquidity coupled with expectations of further rate hikes this year present significant downward pressure. Chinese consumers are increasing their physical gold holdings, providing some support; however, Indian buyers are delaying festival purchases due to expectations that the price decline has not yet ended, substantially weakening demand-side support. For gold prices to regain upward momentum, multiple conditions need to coincide, including a drop in oil prices, cooling inflation, and a weaker US dollar.

华尔街见闻•2026/10/28 08:37

JPMorgan raises the target price of VISA to $455.

格隆汇•2026/10/28 08:31

BUZZ-"Street view" perspective: Benefiting from strong consumer demand and cross-border demand, Visa's business will continue to grow

路透社•2026/10/28 08:26

Net loss narrows by 90% and North American operations turn profitable, but Stellantis (STLA.US) still struggles to relieve cash flow pressure

Stellantis (STLA.US) released its third quarter results on October 28: net revenue reached 37.611 billions euros, an increase of 1% year-on-year, surpassing the market expectation of approximately 36.4 billions euros.

智通财经•2026/10/28 08:22